PRESS RELEASESNeurocrine Biosciences And Idorsia Amend Option Agreement To License Novel Treatment For Rare Pediatric EpilepsyBy PR NewswireJan 9, 2020 8:00 PM EST
OPINIONTuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?By Brian SozziMar 20, 2018 4:43 PM EDT
STOCKS15 Biotech Firms That Have Strong Potential to Be Acquired: JefferiesBy Kinsey GrantMar 20, 2018 2:58 PM EDT
PERSONAL FINANCE10 Sectors That Will Profit Big-Time From Oil's CrashBy Eric ReedJul 16, 2017 1:00 PM EDT
MARKETSWeek in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings BeginBy Valerie YoungApr 13, 2017 6:45 PM EDT
MARKETSU.S. markets close lower as Wall Street grets over global turmoilBy Valerie YoungApr 12, 2017 4:38 PM EDT
MARKETSWall Street Closes Lower Amid Continued Global WorriesBy Valerie YoungApr 12, 2017 1:30 PM EDT
MARKETSStocks Fall as Wall Street Can't Shake Geopolitical ConcernsBy Valerie YoungApr 12, 2017 10:56 AM EDT
STOCKSNeurocrine Biosciences Leads Pre-Market Biotech MoversBy Alicia McElhaneyApr 12, 2017 9:32 AM EDT
STOCKSNeurocrine Biosciences Snags U.S. Approval for Movement Disorder DrugBy Adam FeuersteinApr 11, 2017 5:19 PM EDT
HEALTHPremarket biotech movers: Neurocrine Biosciences, Aralez Pharmaceuticals, QiagenBy Armie Margaret LeeJan 27, 2017 9:46 AM EST
STOCKSAnalysts' Actions -- Ford, Intel, Whirlpool, Wynn and MoreBy TheStreet StaffJan 27, 2017 8:13 AM EST
STOCKSNeurocrine drug fails to reduce tic severity in Tourette Syndrome patientsBy Adam FeuersteinJan 17, 2017 4:19 PM EST
STOCKSThese 5 biotech stocks are ready for a volatility breakBy Robert MorenoSep 14, 2016 6:17 AM EDT
MERGERS AND ACQUISITIONSBiogen should either a buyer or a seller beBy Alicia McElhaneyJul 22, 2016 11:40 AM EDT
MARKETSNeurocrine Biosciences (NBIX) Strong On High Relative Volume TodayBy TheStreet WireMay 31, 2016 10:01 AM EDT
MARKETSInsider Trading Alert - NBIX, FRGI And LBAI Traded By InsidersBy TheStreet WireMay 27, 2016 10:45 AM EDT
MERGERS AND ACQUISITIONSXenoport's cost-cutting tactics lead to buyout with hefty premiumBy Alicia McElhaneyMay 23, 2016 5:43 PM EDT
MARKETSStrong On High Volume: Neurocrine Biosciences (NBIX)By TheStreet WireMay 18, 2016 10:01 AM EDT
JIM CRAMER'Mad Money' Lightning Round: I'm Taking Starbucks Over BojanglesBy Scott RuttApr 8, 2016 6:00 AM EDT
